| To observe the clinical efficacy and safety of Yangzheng Xiaoji capsule combined with chemotherapy in the treatment of advanced non small cell lung cancer.Method:35 patients are treated with Yangzheng Xiaoji capsule combined with chemotherapy while 35 cases as the control group.Results:The two groups recent response rate (CR+PR),the TCM symptom improvement rate were 48.57%,31.43% and 85.71%,54.29%,and the difference was statistically significant (P<0.05) between the two groups; before and after the treatment,the improvement of fatigue, cough, thick sputum,hemoptysis, chest tightness,shortness of breath, chest pain,poor appetite,fever,loins symptom in the treatment group is higher than the control group (P<0.05),spontaneous sweating, heart palpitations and other improvement in the two groups have no significant differences (P>0.05);The improvement in the treatment group of quality of life (KPS),immune indicators (NK cells,T cells subsets),IL II (IL II), tumor necrosis factor (TNF) and clinical benefit rate is higher than the control group,the differences were statistically significant (P<0.05);the side effects of the two groups in hemoglobin,white blood cells,platelets,liver and kidney dysfunction,nausea and vomiting and other reactions,have significant statistically significant(P<0.05);the left had no statistically significance (P>0.05).Conclusion:Yangzheng Xiaoji capsule can effectively treat advanced non small cell lung cancer,improve clinical symptoms and quality of life,improve immune indicators, raised the level of IL Ⅱ and TNF,and reduce the adverse treatment. |
